{"contentid": 488171, "importid": NaN, "name": "EMA/CHMP: six recommendations on extensions of indications", "introduction": "Following its March meeting, the European Medicines Agency\u00e2\u0080\u0099s Committee for Medicinal Products for Human Use (CHMP) announced recommendations for the extension of indications on six already approved drugs.", "content": "<p>Following its March meeting, the European Medicines Agency&rsquo;s Committee for Medicinal Products for Human Use (CHMP) announced recommendations for the extension of indications on six already approved drugs.</p>\n<p>These were as follows:<br /><br /> GlaxoSmithKline&rsquo;s (LSE: GSK) <strong>Benlysta </strong>(belimumab) in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis (LN).&nbsp;</p>\n<p><strong>Kaftrio </strong>(ivacaftor/tezacaftor/elexacaftor), from Vertex Pharmaceuticals (Nasdaq: VRTX), to extend the use in all patients with at least one F508del mutation.</p>\n<p><strong>Kalydeco </strong>(ivacaftor), from Vertex.</p>\n<p>Novo Nordisk&rsquo;s (NOV: N) <strong>Saxenda</strong> (liraglutide) for the treatment of obesity in adolescents aged 12&ndash;17 years.</p>\n<p>Roche&rsquo;s (ROG: SIX) <strong>Tecentriq</strong> (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression*, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberration</p>\n<p>Astellas Pharma&rsquo;s (TYO: 4503) <strong>Xtandi</strong> (enzalutamide) for patients with metastatic hormone-sensitive prostate cancer (mHSPC, also known as metastatic castration-sensitive prostate cancer or mCSPC).</p>\n<p>Additionally, the CHMP issued positive opinions on five novel medicines (<a href=\"https://www.thepharmaletter.com/article/march-ema-chmp-meeting-sees-five-positive-novel-drugs-recommended\">see separate article</a>).</p>", "date": "2021-03-27 13:06:00", "meta_title": "EMA/CHMP: six recommendations on extensions of indications", "meta_keywords": "EMA, CHMP, Indications, Extensions, GlaxoSmithKline, Benlysta, Vertex, Kaftrio, Kalydeco, Novo Nordisk, Saxenda, Roche, Tecentriq, Astellas, Xtandi", "meta_description": "EMA/CHMP: six recommendations on extensions of indications", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-27 15:05:33", "updated": "2021-03-27 15:28:27", "access": NaN, "url": "https://www.thepharmaletter.com/article/ema-chmp-six-recommendations-on-extensions-of-indications", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "ema_big.png", "image2id": "ema_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": "Committee for Medicinal Products for Human Use", "sector_tag": "Pharmaceutical", "therapy area_tag": "Immunologicals, Metabolics, Nutritional disorders, Oncology, Rare diseases", "topic_tag": "European Medicines Agency, Focus On, Regulation", "geography_tag": "Europe", "company_tag": "Astellas, GlaxoSmithKline, Novo Nordisk, Roche, Vertex Pharmaceuticals", "drug_tag": "Benlysta, Kaftrio, Kalydeco, Saxenda, Xtandi", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-27 13:06:00"}